17:39:08 EDT Thu 18 Apr 2024
Enter Symbol
or Name
USA
CA



Shell Summary for Feb. 1, 2019

2019-02-01 20:49 ET - Market Summary

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

by Stockwatch Business Reporter

The TSX Venture Exchange gained a fraction to 622.86 Friday, ending the week up 18.30 points. Two capital pool shells have cancelled the marijuana deals they were working on. First, Larry Doan and David Smalley's Ponderous Panda Capital Corp. (PPCC: halted) called off its acquisition of Trait Biosciences Inc. Panda and Trait apparently failed to agree on terms for the deal. The other shell, Patrick Langlois's Angus Ventures Inc. (GUS: halted), dropped its acquisition of AAA Medic Montreal Inc. Angus provided no reason for the cancellation, which is not unusual. Now that Angus and Panda are no longer working on potential qualifying transactions, they should soon resume trading. Angus already has a resumption date, Feb. 5.

Out of 167 capital pool shells on the exchange, 52 are still working on potential QTs. Of the 52, 14 are working on marijuana or hemp QTs. Nine are working on mining or mining technology deals. Six are working on financial technology deals, for instance involving payment processing or a bill-payment management app. Four are working on real estate development or property management deals. Among the remaining QTs are deals involving advertising (two shells), security systems (two), blockchain (two), graphene (one), a medical device (one), infant formula (one), iced tea (one) and Mexican "dollar" stores called PesoRama (one).

The remainder is available to Stockwatch subscribers.
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

© 2024 Canjex Publishing Ltd. All rights reserved.


Reader Comments - Comments are open to paying subscribers of Stockwatch and unmoderated, although libelous remarks, obscene language and impersonations may be deleted. Opinions expressed do not necessarily reflect the views of Stockwatch.
For information regarding Canadian libel law, please view the University of Ottawa's FAQ regarding Defamation and SLAPPs.


Comments for this item are closed